Drug Shortages due to Brexit: EU gives Answers
Recommendation

27/28 May 2026
Batch Manufacturing Documents: from Preparation to Operational Excellence
If the United Kingdom (UK) leaves the European Union (EU) without a withdrawal agreement ("no deal scenario" or "hard brexit"), EU law will no longer apply in the UK. In this case, companies carrying out certain activities in the UK will have to make changes in order to to comply with EU law and continue to supply medicines in the EU.
The EMA has now published a question-and-answer document and points out that in the event of a withdrawal agreement, there will be a transitional period during which EU law will continue to apply in the UK. This should ensure that access to medicines is not compromised.
The questions and answers explain how the EMA, the European Commission and the EU/EEA Member States have been working closely together since May 2017 to advise companies on how to apply for the necessary changes to minimise the impact on the supply of medicines.
This document applies to both human and veterinary medicines and will be updated as necessary.
Related GMP News
15.04.2026ICH Q9 Training Package updated
01.04.2026New EMA GMP Guidelines in the next three Years
01.04.2026New EMA Guidance: Risk Management for Elemental Impurities in Veterinary Medicinal Products
18.03.2026Sampling in the Focus of the FDA
11.03.2026EU Pharma Package: Final Texts officially published
11.03.2026FDA Guidance Plans for 2026


